文献速递生殖医学

澳大利亚社区女性对抗苗勒管激素检测的认知与使用情况:一项女性人群调查

Community awareness and use of anti-Müllerian hormone testing in Australia: a population survey of women.
PubMed 文献 · Hum Reprod · 2023-01-01

研究对澳大利亚1773名18-55岁女性进行全国横断面调查,发现13%听说过抗苗勒管激素(AMH)检测、7%曾检测;主要检测原因为不孕检查(51%)、考虑妊娠想了解受孕几率(19%)或了解疾病是否影响生育(11%)。作者认为约三分之一检测原因缺乏证据支持,呼吁开展公众和临床医生教育。

要点

  • 在1773名受访女性中,13%听说过AMH检测,7%曾做过AMH检测。
  • 检测率最高见于当前35-39岁女性(14%),且与受教育程度相关。
  • 检测原因包括不孕检查(51%)、考虑妊娠想了解受孕几率(19%)、了解疾病是否影响生育(11%)、好奇(9%)、考虑冻卵(5%)和考虑推迟妊娠(2%)。

核心结论

  • 大多数女性报告因适当原因进行AMH检测,但约三分之一检测原因缺乏证据支持。
  • 作者认为需要就AMH检测对未接受不孕治疗女性缺乏效用开展公众和临床医生教育。

研究设计与样本

  • 2022年1月开展的全国横断面调查,纳入1773名18-55岁女性。
  • 从代表性「Life in Australia」概率人群小组招募,通过在线或电话完成调查。

主要发现

  • 受邀2423名女性中1773名应答(应答率73%)。
  • 229名(13%)听说过AMH检测,124名(7%)曾做过AMH检测。
  • 检测率最高见于当前35-39岁女性(14%),且与受教育程度相关。
  • 几乎所有女性通过全科医生或生育专科医生获取检测。
  • 检测原因包括不孕检查(51%)、考虑妊娠想了解受孕几率(19%)、了解疾病是否影响生育(11%)、好奇(9%)、考虑冻卵(5%)和考虑推迟妊娠(2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量大且大多具有代表性,但大学学位持有者比例过高、18-24岁人群比例过低,已尽可能使用加权数据校正。
  • 所有数据均为自我报告,存在回忆偏倚风险。
  • 调查条目数量受限,未测量女性检测前接受的咨询类型、拒绝AMH检测的原因或检测时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the anti-Mullerian hormone (AMH) test usage, awareness, and perceived reasons for testing in a representative community sample of women in Australia? SUMMARY ANSWER: : Among women aged 18-55 years, 13% had heard about AMH testing and 7% had had an AMH test, with the top three reasons for testing including due to infertility investigations (51%), considering pregnancy and wanting to understand their chances (19%) or to find out if a medical condition had affected fertility (11%). WHAT IS KNOWN ALREADY: The growing availability of direct-to-consumer AMH testing has raised concerns about overuse, however as most AMH tests are paid for privately by consumers, data on test usage is not publicly available. STUDY DESIGN, SIZE, DURATION: National cross-sectional survey of 1773 women, conducted in January 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Females aged 18-55 years were recruited from the representative 'Life in Australia' probability-based population panel and completed the survey online or by telephone. Main outcome measures included if and how participants had heard about AMH testing, whether they had ever had an AMH test, main reason for testing and test access. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 2423 women who were invited 1773 responded (73% response rate). Of these, 229 (13%) had heard about AMH testing and 124 (7%) had had an AMH test. Testing rates were highest among those currently aged 35-39 years (14%) and associated with educational attainment. Almost all accessed the test through their general practitioner or fertility specialist. Reasons for testing were: part of an infertility investigation (51%), considering pregnancy and wanting to understand chances of conceiving (19%), finding out if a medical condition had affected fertility (11%), curiosity (9%), considering egg freezing (5%), and considering delaying pregnancy (2%). LIMITATIONS, REASONS FOR CAUTION: Although the sample was large and mostly representative, it was over-represented by people holding a university degree and under-represented by people aged 18-24, however, we used weighted data where possible to account for this. All data were self-reported so there is a risk of recall bias. The number of survey items was also restricted, so the type of counselling women received prior to testing, reasons for declining an AMH test or test timing were not measured. WIDER IMPLICATIONS OF THE FINDINGS: Whilst most women reported having an AMH test for appropriate reasons, about one third had it for reasons not supported by evidence. Public and clinician education about the lack of utility of AMH testing for women not undergoing infertility treatment is needed. STUDY FUNDING/COMPETING INTEREST(S): This project was supported by a National Health and Medical Research Council (NHMRC) Centre for Research Excellence grant (1104136) and Program grant (1113532). T.C. is supported by an NHMRC Emerging Leader Research Fellowship (2009419). B.W.M. reports research funding, consultancy and travel support from Merck. D.L. is the Medical Director of City Fertility NSW and reports consultancy for Organon, Ferring, Besins and Merck. The authors have no other competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Copp T, Thompson R, Doust J, et al. Community awareness and use of anti-Müllerian hormone testing in Australia: a population survey of women. Hum Reprod. 2023. PMID: 37309652. doi:10.1093/humrep/dead111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。